Evidence map›Paper›PMID 34666102›Full record

ReviewMolecular and biochemical parasitology2021

The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development.

Wilson L Mandala, Visopo Harawa, Fraction Dzinjalamala, Dumizulu Tembo

Open access · hybridAbstract readReview
In one paragraph

Review in Molecular and biochemical parasitology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Hepatorenal protective role of encapsulatedJournal of advanced veterinary and animal research · 2026
    Article
  7. Review
  8. Heme oxygenase-1 and malaria pathogenesis.Frontiers in immunology · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. New therapeutic strategies for malaria.Biophysical reviews · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. IdentifyingResearch square · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Wilson L MandalaAcademy of Medical Sciences, Malawi University of Science and Technology, Thyolo, Malawi; Malawi Liverpool Wellcome Trust, Blantyre, Malawi. Electronic address: wmandala2002@gmail.com.
Visopo HarawaMalawi Liverpool Wellcome Trust, Blantyre, Malawi.
Fraction DzinjalamalaAcademy of Medical Sciences, Malawi University of Science and Technology, Thyolo, Malawi.
Dumizulu TemboMalawi Liverpool Wellcome Trust, Blantyre, Malawi.
University of Liverpool · GBMalawi University of Science and Technology · MW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmodium falciparum malaria still remains a major global public health challenge with over 220 million new cases and well over 400,000 deaths annually. Most of the deaths occur in sub-Saharan Africa which bears 90 % of the malaria cases. Such high P. falciparum malaria-related morbidity and mortality rates pose a huge burden on the health and economic wellbeing of the countries affected. Lately, substantial gains have been made in reducing malaria morbidity and mortality through intense malaria control initiatives such as use of effective antimalarials, intensive distribution and use of insecticide-treated nets (ITNs), and implementation of massive indoor residual spraying (IRS) campaigns. However, these gains are being threatened by widespread resistance of the parasite to antimalarials, and the vector to insecticides. Over the years the use of vaccines has proven to be the most reliable, cost-effective and efficient method for controlling the burden and spread of many infectious diseases, especially in resource poor settings with limited public health infrastructure. Nonetheless, this had not been the case with malaria until the most promising malaria vaccine candidate, RTS,S/AS01, was approved for pilot implementation programme in three African countries in 2015. This was regarded as the most important breakthrough in the fight against malaria. However, RTS,S/AS01 has been found to have some limitations, the main ones being low efficacy in certain age groups, poor immunogenicity and need for almost three boosters to attain a reasonable efficacy. Thus, the search for a more robust and effective malaria vaccine still continues and a better understanding of naturally acquired immune responses to the various stages, including the transmissible stages of the parasite, could be crucial in rational vaccine design. This review therefore compiles what is currently known about the basic biology of P. falciparum and the natural malaria immune response against malaria and progress made towards vaccine development.

Indexed as

AntimalarialsMalariaMalaria, FalciparumMalaria VaccinesHumansImmune SystemPlasmodium falciparumVaccine DevelopmentAntimalarialsMalaria VaccinesImmune cellsMalariaVaccine candidates

Identifiers

PMID34666102
PMCPMC8655617
OpenAlexW3205222046

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.